Hutchinson-Gilford progeria syndrome, also known as progeria, is an extremely rare genetic disorder that causes children to suffer symptoms of accelerated ageing. It’s caused by a mutation in the gene that encodes a protein called lamin A, which provides structural support for the cell’s control centre or nucleus. With the faulty protein, nuclei are misshapen and unstable (right), unlike the spherical shape of a healthy nucleus (left). The disorder is invariably fatal, with most patients dying of heart disease in their teens. But clinical trials have recently returned encouraging, if mixed, results for a repurposed cancer drug called lonafarnib, which is thought to deactivate the defective scaffolding protein. Nine of the 25 trial subjects gained weight – something progeria patients struggle with – while 18 experienced improvements in the flexibility of blood vessels, potentially reducing the risk of heart attack and stroke. A second trial is ongoing.
Written by Daniel Cossins
BPoD stands for Biomedical Picture of the Day. Managed by the MRC London Institute of Medical Sciences the website aims to engage everyone, young and old, in the wonders of biomedicine. Images are kindly provided for inclusion on this website through the generosity of scientists across the globe.
BPoD is also available in Catalan at www.bpod.cat with translations by the University of Valencia.